Abbott
Patients are virtually guided through the steps of sample collection and testing.
More than 11 million Canadians live with diabetes or prediabetes, making up 29% of the country’s population.
The new device is smaller than previous versions.
The pharma giant is collaborating with sports tech firm Supersapiens.
The updated version of the company's system includes automatic alerts when the wearer's glucose is too high or too low.
Also: Abbott sells 150 million of its rapid, app-paired COVID-19 test to the White House; Platform launches for chronic disease patients juggling multiple providers.
Users are also able to access a corresponding app, which can keep track of their coronavirus test results.
Also: Dexcom continues to make strides, while iRhythm Technologies takes a hit in Q2.
The Patient Controller app works with Abbott's Infinity DBS System, Proclaim XR SCS System and Proclaim DRG Neurostimulation System.
The new devices can link to the MyMerlinPulse app and give doctors information about a patient's heart health.